Dr. Michael F. Carter, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 455
Licensed in Alabama since 1998, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Alabama School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
AL license 21997 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Huntsville Hospital Huntsville, AL
- Crestwood Medical Center Huntsville, AL
Medical groups
- Michael F Carter MD PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 455
- Services billed
- 4,802
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 1,200 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 768 | 396 |
| Injection, dexamethasone sodium phosphate, 1 mg | 461 | 44 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 454 | 228 |
| Established patient office or other outpatient visit, 20-29 minutes | 360 | 225 |
| Advance care planning, first 30 minutes | 350 | 350 |
| Annual depression screening, 5 to 15 minutes | 335 | 335 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 326 | 326 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 297 | 285 |
| Administration of influenza virus vaccine | 180 | 180 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 95 payments worth $1,589 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $468 |
|---|---|
| Novo Nordisk Inc | $260 |
| Pfizer Inc. | $169 |
| Lilly USA, LLC | $139 |
| Amgen Inc. | $71.09 |
| Phathom Pharmaceuticals, Inc. | $67.54 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.23 |
| Exact Sciences Corporation | $65.42 |
| Food and Beverage | $1,589 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $809,946 in research payments for these studies, mostly to the institutions running them.
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A phase 3 multicenter parallelgroup openlabel study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion f subunit vaccine when coadministered with herpes zoster subunit vacc…
Pfizer Inc. - A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction …
Ibsa Institut Biochimique SA - A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged…
Janssen Research & Development, LLC - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc. - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.